



Bringing to life the b



The English language The National Library for Health and the National Guidelines Clearing House were also searched for relevant guidelines. Where possible, recommendations are based on available evidence, areas where evidence is lacking are annotated as good practice points (designated by a tick).

## 4. Preconception care

*4.1.1.1. What are the additional risks to the woman and baby*

SCD is associated with both maternal and fetal complications and is associated with an increased incidence of perinatal mortality, - pre-term labour, - fetal growth restriction - and acute painful crises during pregnancy.

The assessment for iron overload complications should include:

- Screening for pulmonary hypertension with echocardiography. The incidence of pulmonary hypertension is increased in patients with SCD and is associated with increased mortality. A tricuspid regurgitant jet velocity of more than 2.5 m/s is associated with a high risk of pulmonary hypertension. Screenings should be performed if this has not been carried out in the last year.
- Blood pressure and urinalysis should be performed to identify women with hypertension and/or proteinuria, renal and liver function tests should be performed annually to identify silent nephropathy and/or deranged hepatic function.
- Retinal screening proliferative retinopathy is common in patients with SCD, especially patients with HbSC, and can lead to loss of vision. There is no randomised evidence on whether routine screenings should be performed or if patients should be screened only if they experience visual symptoms, but we recommend that women are screened proactively.
- Screening for iron overload. In women who have been multiply transfused in the past or who have a high ferritin level, <sup>51</sup>Cr-labelled magnetic resonance imaging may be helpful to assess body iron loading. Aggressive iron chelation before conception is advisable in women who are significantly iron loaded.
- Screening for red cell antibodies. Red cell antibodies may indicate an increased risk of neonatal disease of the newborn.

... at the importance of genetic screening and what procedures are involved

Women and men with SCD should be encouraged to have the haemoglobinopathy status of their partner determined before they embark on pregnancy. If identified as an 'at risk couple', as per National Screening Committee guidance, they should receive counselling and advice about reproductive options.



General practitioners have a role to play in partner screening and genetic counselling. Women should be encouraged to have the haemoglobinopathy status of their partner tested. If a partner is a carrier of, or affected by, a major haemoglobinopathy, the couple should receive appropriate counselling regarding the risk of having affected offspring (Table 1). The benefits and risks of prenatal diagnosis and termination of pregnancy should be discussed with the couple. In addition, they should receive counselling about the availability of pre-implantation genetic diagnosis and referred to it if appropriate. Partners will not always be available or willing to undergo pre-conceptual testing. Women with SCD should be aware that if their partner's status is unknown, the fetus should be treated as high risk for a haemoglobinopathy. Sperm donors should also be screened for haemoglobinopathies for couples considering in vitro fertilisation.

Further information can be obtained from the HbS-Sickle Cell & T Assessment in Screening Program website or the program's *Handbook for Laboratories*.

**Table 1. Conditions requiring counselling when the other is affected by SCD<sup>35</sup>**

Condition	Counselling	Prenatal diagnosis	Pre-implantation genetic diagnosis
HbS	Yes	Yes	Yes



pregnant while taking Ydro Y ~rb~ ide, it should be stopped and a level ultrasound performed to look for structural abnormalities, but termination is not indicated based on exposure to Ydro Y ~rb~ ide alone.



It is recommended that women receive low-dose aspirin during hospital admission

Non-steroidal anti-inflammatory drugs (NSAIDs) should be prescribed only between 34 and 36 weeks of gestation owing to concerns regarding adverse effects on fetal development

*Additional care should be provided during antenatal appointments*

Antenatal appointments for women with SCD should provide routine antenatal care as well as care specifically for women with SCD.





'Top-up' transfusion is indicated for women with acute anaemia. Acute anaemia may be attributable to transient red cell aplasia, acute splenic sequestration or to increased red cell loss and volume expansion encountered in SCD. There is no absolute level at which transfusion should be undertaken and the decision must be made in conjunction with clinical findings, but a haemoglobin under 7g/dl or a fall of over 1g/dl from baseline is often used as a guide to transfusion requirement.

Erythrocyte transfusion (or ACS) was demonstrated to be effective in one prospective randomised trial and is accepted as best practice.

Erythrocyte transfusion is also indicated for acute stroke.

The decision to receive transfusion should be made by an experienced haematologist and obstetrician. Indications for transfusion are summarised in Table 1.

Allotransfusion (transfer of antibodies to red cell antigens) is common in SCD, occurring in



Fluid intake of at least 1.5 l/gours should be ensured to ensure adequate oral fluids. There is a risk of fluid overload in women with pre-eclampsia, senior experience staff should be involved in managing the fluid balance of these women. Oxygen saturations should be monitored and supplemental oxygen should be prescribed if oxygen saturation falls below the woman's baseline or below 95%. There should be early recourse to intensive care if saturations cannot be maintained by supplemental oxygen administration.

The woman should be assessed for infection. Therapeutic antibiotics should be prescribed if the woman is febrile or there is a significant clinical suspicion of infection. White blood cell counts are often raised in SCD and do not necessarily indicate infection. Troponin levels should be provided to women with SCD who are admitted to hospital with painful crises. Other adjuvants may be required to treat the adverse effects of opiates, such as anti-emetics to treat itching or laxatives to prevent opiate-induced constipation, and anti-eclampsia may be required. As the painful crisis resolves, most women are able to reduce their opiate requirements rapidly, but this should be guided by the woman's previous experience.

Opiates are not associated with teratogenicity or congenital malformation but may be associated with transient suppression of fetal movement and reduced baseline variability of the fetal heart rate. Where other analgesics are received prolonged administration of opiates in late pregnancy, the neonate should be observed for signs of opioid withdrawal.

#### Other acute complications of SCD and how they are treated

All patients, carers, medical and nursing staff should be aware of the other acute complications of SCD, including ACS, acute stroke and acute anaemia.

Each hospital should have a protocol in place for the management of ACS in pregnancy, including the use of transfusion therapy.

SCD is associated with other acute complications including ACS, stroke and acute anaemia. In the pregnant woman, these complications should be managed in the multidisciplinary setting by an obstetrician and a haematologist, and guidance on the management of these complications can be found in the relevant standards.

After acute pain, ACS is the most common complication, reported in 10% of pregnancies. ACS is characterised by respiratory symptoms such as tachypnoea, chest pain, cough and shortness of breath in the presence of a new infiltrate on the chest X-ray. The signs and symptoms of ACS are the same as those of pneumonia, so both should be treated simultaneously. Acute severe infection with the H1N1 virus in pregnancy can cause a similar clinical picture, and investigation and treatment for this should be instituted.

Acute stroke, both ischaemic and haemorrhagic, is associated with SCD

The relevant multidisciplinary team (senior midwife in charge, senior obstetrician, anaesthetist and haematologist) should be informed as soon as labour is confirmed.

Women should be kept warm and given adequate fluid during labour.

Continuous intrapartum electronic fetal heart rate monitoring is recommended owing to the increased risk of fetal distress which may necessitate operative delivery.

There are no randomised controlled trials with regard to place of birth for women with SCD. There is an increased frequency of stillbirths and ACS in the intrapartum period. There is an increased risk of painful crisis with protracted labour (more than 6 hours), but this is often secondary to dehydration. In this situation, if the woman is well hydrated and labour is progressing, the labour should be carefully supervised. Caesarean section should be considered if labour is not progressing well and delivery is not imminent.

During labour, if oral hydration is not tolerated or is inadequate, intravenous fluids should be administered using a fluid balance sheet to prevent fluid overload. Venous access can be difficult, especially if there have been multiple previous admissions, and as such anaesthetic review/intravenous access should be obtained early. The degree of oxygenation is increased during the intrapartum period and the use of pulse oximetry to detect hypoxia in the mother is appropriate during labour. Arterial blood gas analysis should be performed and oxygen therapy instituted if oxygen saturation is 90% or less.

Routine antibiotic prophylaxis in labour is currently not supported by evidence, but our observations of vital signs should be performed. A raised temperature (over 38.0°C) requires investigation. The clinician should have a low threshold to commence broad-spectrum antibiotics.

There are no randomised controlled trials with regard to interventions during labour for women with SCD. Experience reported in cohort observational studies for stillbirth rates in Jamaica, Nigeria, the USA and the UK recommend close observation, as described above. Continuous electronic fetal heart rate monitoring is recommended because of the increased rate of stillbirth, placental abruption and hypoplastic placental reserve.

#### *Management at the optimal mode of anaesthesia and anaesthetics*

Women with SCD should be offered anaesthetic assessment in the third trimester of pregnancy.

Avoid the use of pethidine, but other opiates can be used.

Regional analgesia is recommended for caesarean section.

Pregnant women with SCD are at risk of end-organ damage as well as experiencing a higher rate of caesarean section. General anaesthesia carries additional risks beyond the normal obstetric risks and should be avoided where possible. Regional anaesthesia during labour may reduce the need for general anaesthesia for delivery. It is also likely to reduce the need for high doses of opioids if the woman has similar-related pain in the lower body. An anaesthetic assessment in the third trimester is warranted. Pethidine should be avoided.

## 7. Postpartum care

*It should be the optimum care post delivery*

In pregnant women where the baby is at high risk of SCD (i.e. the partner is a carrier or affected), early testing for SCD should be offered. Capillary samples should be sent to laboratories where there is experience in the routine analysis of SCD in newborn samples. This will usually be at a regional centre.

Maintain maternal oxygen saturation above 94% and adequate hydration based on fluid balance until discharge.

Low-molecular-weight heparin should be administered while in hospital and 7 days post-discharge following vaginal delivery or for a period of 6 weeks following caesarean section.

The same level of care and vigilance should be maintained as has been described for antenatal care,

- Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell disease: a molecular disease. *Science* 1948; 103: 37-41.
- Stuart NJ. Sickle cell disease. *Lancet* 1990; 335: 100-104.





1. Kos Y M, Burd G, Yancey D, Mowbray A, Baron J. Propylthiouracil  
reduces cell transfusions in pregnant patients with sickle cell  
disease: A randomized cooperative study. *N Engl J Med*

## APPENDIX

Clinical guidelines are systematically developed statements with which assist clinicians and women in making decisions about appropriate treatment or specific conditions. Each guideline is systematically developed using a standardised methodology. Further details of this process can be found in Clinical Governance Advice on *Development of RCOG Green-top Guidelines* (available on the RCOG website at <http://www.rcog.org.uk>). These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research might be indicated.

The evidence used in this guideline was graded using the scheme below and the recommendations formulated in accordance with standardised grading scheme.

Classification	Recommendation
<p>++ High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias</p>	<p><b>A</b> At least one meta-analysis, systematic review or randomised controlled trial rated as ++ and directly applicable to the target population, or</p>
<p>+ Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias</p>	<p>A systematic review of randomised controlled trials or a body of evidence consisting principally of studies rated as + directly applicable to the target population and demonstrating overall consistency of results</p>
<p>- Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias</p>	<p><b>B</b> A body of evidence including studies rated as ++ directly applicable to the target population, and demonstrating overall consistency of results, or</p>
<p>++ High-quality systematic reviews of case-control or cohort studies or high-quality case-control or cohort studies with a very low risk of confounding, bias or imprecision and a high probability that the relationship is causal</p>	<p>E extrapolated evidence from studies rated as ++ or +</p> <p><b>C</b> A body of evidence including studies rated as + directly applicable to the target population and demonstrating overall consistency of results, or</p>
<p>+ Well-conducted case-control or cohort studies with a low risk of confounding, bias or imprecision and a moderate probability that the relationship is causal</p>	<p>E extrapolated evidence from studies rated as ++</p> <p><b>D</b> Evidence level or , or</p>
<p>- Case-control or cohort studies with a high risk of confounding, bias or imprecision and a significant risk that the relationship is not causal</p>	<p>E extrapolated evidence from studies rated as +</p> <p><b>oo</b> <b>pr</b> <b>po</b> <b>n</b></p>
<p>Non-analytical studies, e.g. case reports, case series</p> <p>Expert opinion</p>	<p><input checked="" type="checkbox"/> Recommended best practice based on the clinical experience of the guideline development group</p>

This guideline was produced on behalf of the Guidelines Committee of the Royal College of Obstetricians and Gynaecologists by:

Dr Ewen Ross FRCS Consultant in Gynaecology, Dr Gordon Ross Consultant in Gynaecology, Dr Gordon Ross Consultant in Gynaecology

Professor E Anionwu, Emeritus Professor of Nursing, Thames Valley University and Single Cell Society, Mr I Babarinsa, MRCOG, Gloucester, Dr C Bagot, Consultant Haematologist, Glasgow, Mr DI Fraser MRCOG, Morriston, Dr Jane Preston FRCS, Dr V Emejeji, MRCOG, Consultant and General Haematologist, Tayside, British Committee for Standards in Haematology, Ms Stuart FRCS, London, British Committee for Standards in Haematology, British Maternal and Fetal Medicine Society, Dr Allison Streetly, National Screening Committee, Obstetric Anaesthetists' Association, Royal College of General Practitioners, RCGP Consumers' Forum, Royal College of Midwives, World Health Organization

The Guideline Committee lead reviewers were: Dr J Sillito MRCOG, Leeds and Dr S Suresh MRCOG, London  
Conflicts of interest: none declared

The guidelines review process will continue unless evidence requires earlier review

#### DISCLAIMER

The Royal College of Obstetricians and Gynaecologists produces guidelines as an educational aid to good clinical practice. They present recognised methods and techniques of clinical practice, based on published evidence, for consideration by obstetricians and gynaecologists and other relevant health professionals. The ultimate judgement regarding a particular clinical procedure or treatment plan must be made by the doctor or other attendant in the light of clinical judgement presented by the patient and the diagnostic and treatment options available within the appropriate health services.

This means that RCOG Guidelines are unlike protocols or guidelines issued by employers, as they are not intended to be prescriptive directions defining a single course of management. Departure from the local prescriptive protocols or guidelines should be fully documented in the patient's case notes as the time the relevant decision is taken.